Mycronic AB (SE:MYCR)
:MYCR
Want to see SE:MYCR full AI Analyst Report?
Top Page
Mycronic AB
(MYCR)
Select Model
Select Model
Rating:71Outperform
Price Target:
kr335.00
▲(54.66% Upside)
Action:UpgradedDate:04/26/26
The score is driven mainly by strong profitability and a conservatively financed balance sheet, offset by recent free-cash-flow weakness (reported as 0 in 2025 and TTM). Technically, the trend is strong but indicators are overbought, and valuation is stretched given the high P/E and modest yield.
Positive Factors
Healthy margins
Sustained high gross and operating margins indicate durable product-level economics and pricing power in capital equipment and aftermarket. These margins support reinvestment in R&D and service capability, enable attractive ROE (~22%), and provide a buffer through industry cycles.
Negative Factors
Free cash flow volatility
A sudden collapse to zero FCF despite positive operating cash flow suggests elevated capex or working-capital swings. Persistent FCF volatility undermines ability to consistently fund dividends, buybacks, or opportunistic investment and raises execution risk over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Healthy margins
Sustained high gross and operating margins indicate durable product-level economics and pricing power in capital equipment and aftermarket. These margins support reinvestment in R&D and service capability, enable attractive ROE (~22%), and provide a buffer through industry cycles.
Read all positive factors
Mycronic AB (MYCR) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr58.16B
Dividend Yield1.71%
Average Volume (3M)171.55K
Price to Earnings (P/E)14.9
Beta (1Y)0.98
Revenue Growth10.54%
EPS Growth-8.85%
CountrySE
Employees2,318
SectorGeneral
Sector StrengthN/A
IndustryIndustrial - Machinery
Share Statistics
EPS (TTM)8.47
Shares Outstanding195,833,020
10 Day Avg. Volume161,326
30 Day Avg. Volume171,548
Financial Highlights & Ratios
PEG Ratio-3.77
Price to Book (P/B)6.13
Price to Sales (P/S)5.49
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.76
Revenue Forecast (FY)kr8.23B
Mycronic AB Business Overview & Revenue Model
Company Description
Mycronic AB (publ), together with its subsidiaries, develops, manufactures, and sells production equipment for electronics industry in Sweden, rest of Europe, the United States, other Americas, China, South Korea, rest of Asia, and internationally...
How the Company Makes Money
Mycronic primarily makes money by selling complex, high-value capital equipment used in electronics and semiconductor production, complemented by recurring aftermarket revenues. Key revenue streams typically include: (1) New equipment sales: Reven...
Mycronic AB Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.30B | 7.94B | 7.06B | 5.71B | 5.12B | 4.63B |
| Gross Profit | 4.31B | 4.12B | 3.72B | 2.72B | 2.29B | 2.28B |
| EBITDA | 2.42B | 2.30B | 2.32B | 1.39B | 1.11B | 1.20B |
| Net Income | 1.66B | 1.56B | 1.68B | 998.00M | 741.00M | 828.00M |
Balance Sheet | ||||||
| Total Assets | 11.94B | 10.92B | 10.41B | 8.34B | 7.34B | 6.14B |
| Cash, Cash Equivalents and Short-Term Investments | 2.72B | 2.32B | 3.01B | 2.14B | 1.27B | 683.00M |
| Total Debt | 401.00M | 348.00M | 219.00M | 228.00M | 270.00M | 243.00M |
| Total Liabilities | 4.07B | 3.81B | 3.84B | 3.06B | 2.64B | 2.14B |
| Stockholders Equity | 7.87B | 7.11B | 6.53B | 5.25B | 4.66B | 3.96B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 0.00 | 1.64B | 1.41B | 712.00M | 908.00M |
| Operating Cash Flow | 1.78B | 1.41B | 1.87B | 1.61B | 853.00M | 998.00M |
| Investing Cash Flow | -1.18B | -1.13B | -500.00M | -195.00M | 67.00M | -1.22B |
| Financing Cash Flow | -863.00M | -862.00M | -552.00M | -447.00M | -382.00M | -437.00M |
Mycronic AB Technical Analysis
Positive
216.60
Price Trends
212.64
Positive
213.22
Positive
212.70
Positive
Market Momentum
13.05
Negative
81.44
Negative
94.35
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MYCR, the sentiment is Positive. The current price of 216.6 is below the 20-day moving average (MA) of 229.49, above the 50-day MA of 212.64, and above the 200-day MA of 212.70, indicating a bullish trend. The MACD of 13.05 indicates Negative momentum. The RSI at 81.44 is Negative, neither overbought nor oversold. The STOCH value of 94.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:MYCR.
Mycronic AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr85.59B | 20.02 | 9.65% | 1.95% | -2.11% | 1.86% | |
72 Outperform | kr462.87B | 28.92 | 16.39% | 1.94% | -0.90% | 0.66% | |
71 Outperform | kr58.16B | 14.88 | 22.44% | 1.71% | 10.54% | -8.85% | |
71 Outperform | kr844.31B | 28.20 | 26.43% | 2.03% | -5.93% | -10.65% | |
69 Neutral | kr224.60B | 27.89 | 20.42% | 1.84% | 0.90% | 6.26% | |
68 Neutral | kr844.31B | 31.77 | 24.69% | 1.82% | -5.93% | -10.65% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
SE:MYCR
Mycronic AB
297.00
94.92
46.97%
SE:ALFA
Alfa Laval AB
543.40
136.99
33.71%
SE:ATCO.B
Atlas Copco AB
158.70
20.41
14.76%
SE:ATCO.A
Atlas Copco AB
180.40
21.92
13.83%
SE:SAND
Sandvik AB
369.00
154.60
72.11%
SE:TREL.B
Trelleborg AB
390.60
32.85
9.18%
Mycronic AB Corporate Events
Mycronic Lifts 2026 Sales Target After Record First-Quarter Earnings
Apr 24, 2026
Mycronic opened 2026 with record quarterly performance, as order intake rose 23 percent to SEK 2,529 million and net sales climbed 17 percent to SEK 2,503 million, or 32 percent at constant exchange rates. EBIT reached an all-time high of SEK 938 ...
Mycronic Wins Major Customized SLX Mask Writer Order From New Semiconductor Customer
Apr 14, 2026
Mycronic’s Pattern Generators division, which supplies mask writers and metrology systems for display and semiconductor production, has secured a significant new customer for its SLX laser mask writer platform. The SLX system, based on the c...
Mycronic sets date for Q1 2026 results webcast
Apr 10, 2026
Mycronic has invited analysts, investors and media to a webcast presentation of its first-quarter 2026 results, scheduled for April 24 at 10:00 a.m. CEST, with the interim report to be published earlier that morning and made available in the compa...
Mycronic Wins USD 5–7 Million SLX Mask Writer Order from Asian Customer
Mar 27, 2026
Mycronic has secured an order worth USD 5-7 million from an existing Asian customer for its SLX laser mask writer, with delivery scheduled for the second quarter of 2027. The deal underscores growing demand for energy-efficient, modern photomask p...
Mycronic convenes 2026 AGM with flexible voting and facility tour
Mar 25, 2026
Mycronic AB has called its Annual General Meeting for May 6, 2026, at the company’s premises in Täby, giving shareholders the choice to participate in person, by proxy or via postal voting in line with the Swedish Companies Act. Shareho...
Mycronic strengthens leadership with new Senior Vice President People & Culture
Feb 26, 2026
Mycronic has appointed Annika Haaker as Senior Vice President People Culture and member of the Executive Management team, with her latest start date set for August 17, 2026. Haaker, who currently serves as Chief People Culture Officer at Alimak ...
Mycronic Delivers Record 2025 Sales but Lower Margin as Investments and AI Demand Shape Outlook
Feb 5, 2026
Mycronic AB reported a record 2025 in terms of both order intake and net sales, with full-year order intake rising 2% to SEK 7.76 billion and net sales up 12% to SEK 7.94 billion, despite currency headwinds. EBIT for the year slipped to SEK 1.94 b...
Mycronic Wins USD 21–24 Million Prexision 8 Evo Order from Asian Customer
Feb 4, 2026
Mycronic has secured a replacement order from an existing Asian customer for a Prexision 8 Evo mask writer, a system designed to handle complex patterns for advanced display photomasks, with an order value estimated between USD 21 million and USD ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.